We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 05, 2021

Efficacy of Ivosidenib for Patients With Advanced Cholangiocarcinoma With an IDH1 Mutation

JAMA Oncology

 

Additional Info

JAMA Oncology
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
JAMA Oncol 2021 Sep 23;[EPub Ahead of Print], AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, JM Cleary, DVT Catenacci, MJ Borad, JA Bridgewater, WP Harris, AG Murphy, DY Oh, JR Whisenant, MA Lowery, L Goyal, RT Shroff, AB El-Khoueiry, CX Chamberlain, E Aguado-Fraile, S Choe, B Wu, H Liu, C Gliser, SS Pandya, JW Valle, GK Abou-Alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading